<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813643</url>
  </required_header>
  <id_info>
    <org_study_id>100000-068941</org_study_id>
    <nct_id>NCT01813643</nct_id>
  </id_info>
  <brief_title>A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis</brief_title>
  <official_title>A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Hao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or
      environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical
      presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),
      response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic
      neurotransmission) of both conditions. Both risperidone and aripiprazole are second
      generation antipsychoticsï¼Œbut have different pharmacological effects of antipsychotic
      treatment.This study was designed to examine the acute efficacy, safety, and tolerability of
      risperidone and aripiprazole for patients with MAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:A Multiple-Center, Randomized, Double-Blind.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Effects of aripiprazole was not obvious and showed adverse reaction obviously
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The severity of psychosis</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <description>Positive and Negative Syndrome Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse drug reaction</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital</time_frame>
    <description>Barnes Scale , Simpson-Angus Scale , Abnormal Involuntary Movement Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical general status</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <description>Clinical general rating scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal H20070057</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Aopai H20041507</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)
             criteria for Methamphetamine-Associated Psychosis.

          2. Must sign a Information consent form.

          3. Required to provide detailed address and phone number

        Exclusion Criteria:

          1. Serious organic disease.

          2. Suicide ideation or hurt others.

          3. Taking antipsychotic within two weeks before.

          4. drug allergy to Risperidone or Aripiprazole.

          5. pregnancy and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Hao, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Wei Hao</investigator_full_name>
    <investigator_title>The Second Xiangya Hospital of Cental South University</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine-Associated Psychosis</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Risperidone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

